Curcumin For The Treatment Of Major Depression: A Randomised, Double-blind, Placebo Controlled Study
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 56 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44, 45-64 |
| Body Types | Average |
A total of 56 individuals with MDD were treated with 500 mg of BCM-95 curcumin (twice daily) or placebo for eight weeks. The primary measure was the IDS-SR30. Secondary outcomes included IDS-SR30 factor scores and the STAI. After eight weeks, The curcumin group experienced a 33.1% decrease in IDS-SR30 scores, a 19% decrease in STAI-S scores and a 14.8% decrease in STAI-T scores.Funding issues for this study:
Funding for this study was provided by Arjuna Natural Extracts Limited.
